• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Trump, industry groups praise outgoing FDA chief Gottlieb

Trump, industry groups praise outgoing FDA chief Gottlieb

March 6, 2019 By Sarah Faulkner

FDA's Dr. Scott GottliebIn the wake of the surprising news that FDA commissioner Dr. Scott Gottlieb plans to resign next month, the Trump Administration and industry groups expressed support for the outgoing chief.

In a letter to FDA employees, Gottlieb said that the challenge of being apart from his family for the last two years motivated his decision to leave. An administration official told CNN that Gottlieb has been commuting weekly from his home in Connecticut to Washington.

During his tenure at the FDA, Gottlieb oversaw a record number of approvals for new drugs and therapies. He focused his policy priorities on dealing with opioid addiction and e-cigarettes.

Gottlieb also dealt with overseeing the FDA during the longest government shutdown in history, as well as navigating the difficulties presented by natural disasters.

Secretary of the Dept. of Health & Human Services Alex Azar wrote that Gottlieb has been “an exemplary public health leader, aggressive advocate for American patients, and passionate promoter of innovation.”

The president took to Twitter to support Gottlieb.

“Scott Gottlieb, who has done an absolutely terrific job as Commissioner of the FDA, plasn to leave government service sometime next month,” he wrote. “Scott has helped us to lower drug prices, get a record number of generic drugs approved and onto the market, and so many other things. He and his talents will be greatly missed!”

Medical device industry groups also commented on Gottlieb’s departure.

“Commissioner Gottlieb has been a tremendous leader in supporting patient care and medical technology innovation, and he has initiated regulatory reforms that will impact our ecosystem for years to come. MDMA thanks Commissioner Gottlieb for all of his passionate work, and we look forward to continue working with the Administration, FDA, Congress and all stakeholders to ensure that patients have timely access to safe and effective medical technologies,” Mark Leahey, president & CEO of the Medical Device Manufacturers Association, said in prepared remarks.

“We want to thank Dr. Gottlieb for his service to the American public and his commitment to ensuring patients have access to the latest treatments, diagnostics and cures. During his tenure as FDA commissioner, Dr. Gottlieb has been a tireless advocate for improved patient care and for promoting innovative solutions to our most pressing health challenges, including greater use of medtech to combat the opioid crises. We wish him well in his future endeavors,” AdvaMed president & CEO Scott Whitaker said in a statement.

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: AdvaMed, FDA

More recent news

  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy